non-cystic fibrosis bronchiectasis
Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
The deal includes an early-stage combination vaccine candidate for RSV and hMPV
Merck to expand respiratory disease portfolio with $10bn Verona acquisition
The deal includes a drug approved in the US for chronic obstructive pulmonary disease
International Respiratory Coalition urges policymakers to help lift disease burden
The societal and economic cost of respiratory disease in Europe is reportedly over €600bn
Infex doses first patients in Pseudomonas aeruginosa phase 1 study
Pa is a leading cause of non-cystic fibrosis bronchiectasis exacerbations
MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments
FDA panel rejects Aradigm/Grifols’ inhaled antibiotic
Further evidence is required to warrant approval according to the US regulator
AstraZeneca to explore link between epigenetics and respiratory diseases
Joins forces with Asthma UK, the British Lung Foundation and MRC Technology
Successful partnerships in pharma: Skyepharma and Mundipharma
Why skills and flexibility matter more than sheer size
Mixed messages for AZ’s benralizumab in COPD study
Respiratory hope misses primary goal in trial data presented at ERS congress
GSK trial throws everything at COPD
Tests combination of fluticasone furoate, umeclidinium and vilanterol